Menu
Close
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
99% of eligible, commercially insured patients are covered for XELJANZ® (tofacitinib)
99% = 169 of 170 million commercial lives covered by insurance with no step, or 1 step edit, and/or 2 step edits. Number of covered commercial lives does not represent the number of patients with RA. Plan coverage may differ from approved XELJANZ full prescribing information. XELJANZ is approved for use in patients who have had inadequate response or intolerance to TNF blockers.
Data on file. Pfizer Inc., New York, NY. Source: XELJANZ Market Formulary Status Summary, MMIT July 2023. Check directly with health plans to confirm coverage for individual patients. The information provided is not a guarantee of coverage. Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.
99% of eligible, commercially insured patients are covered for XELJANZ® (tofacitinib)
99% = 169 of 170 million commercial lives covered by insurance with no step, or 1 step edit, and/or 2 step edits. Number of covered commercial lives does not represent the number of patients with RA. Plan coverage may differ from approved XELJANZ full prescribing information. XELJANZ is approved for use in patients who have had inadequate response or intolerance to TNF blockers.
Data on file. Pfizer Inc., New York, NY. Source: XELJANZ Market Formulary Status Summary, MMIT July 2023. Check directly with health plans to confirm coverage for individual patients. The information provided is not a guarantee of coverage. Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.
Eligible, commercially insured patients may pay as little as $0 out-of-pocket costs, with a maximum benefit of $4,000-$15,000 per calendar year depending on insurance.
To determine eligibility and to enroll, direct your patients to:
Limits, terms, and conditions may apply. Federal and state healthcare beneficiaries ineligible. No membership fee. Offer not valid for cash-paying patients. See Terms & Conditions.
If a delay or coverage denial occurs during the prior authorization or appeals process, eligible, commercially insured patients enrolled in XELSOURCE may receive XELJANZ for up to two years at no cost shipped to them through Interim Care Rx.
See Terms & Conditions.
The free product for this program is for certain commercially insured patients only. See Terms & Conditions. Not available to residents in the states of MA, MI, MN, and RI.
If your patient is new to XELJANZ, you can help get them started on their treatment with a one-time, 30-day supply of XELJANZ.
Patients with commercial insurance, Medicare Part D, or Medicaid, or who are underinsured or uninsured and are new to XELJANZ, are eligible.
See Terms & Conditions.
Eligible, commercially insured patients may pay as little as $0 out-of-pocket costs, with a maximum benefit of $4,000-$15,000 per calendar year depending on insurance.
To determine eligibility and to enroll, direct your patients to:
Limits, terms, and conditions may apply. Federal and state healthcare beneficiaries ineligible. No membership fee. Offer not valid for cash-paying patients.
See Terms & Conditions.
If a delay or coverage denial occurs during the prior authorization or appeals process, eligible, commercially insured patients enrolled in XELSOURCE may receive XELJANZ for up to
two years at no cost shipped to them through Interim Care Rx.
See Terms & Conditions.
The free product for this program is for certain commercially insured patients only. See Terms & Conditions. Not available to residents in the states of MA, MI, MN, and RI.
If your patient is new to XELJANZ, you can help get them started on their treatment with a one-time, 30-day supply of XELJANZ.
Patients with commercial insurance, Medicare Part D, or Medicaid, or who are underinsured or uninsured and are new to XELJANZ, are eligible.
See Terms & Conditions.
Eligible, commercially insured patients may pay as little as $0 out-of-pocket costs, with a maximum benefit of $4,000-$15,000 per calendar year depending on insurance.
To determine eligibility and to enroll, direct your patients to:
If a delay or coverage denial occurs during the prior authorization or appeals process, eligible, commercially insured patients enrolled in XELSOURCE may receive XELJANZ for up to
two years at no cost shipped to them through Interim Care Rx.
See Terms & Conditions.
If your patient is new to XELJANZ, you can help get them started on their treatment with a one-time, 30-day supply of XELJANZ.
Patients with commercial insurance, Medicare Part D, or Medicaid, or who are underinsured or uninsured and are new to XELJANZ, are eligible.
See Terms & Conditions.
Field Reimbursement Manager (FRM)
At any point in the medication access journey for prescribed patients, you can get in touch with a Field Reimbursement Manager, a designated Pfizer field colleague. They are familiar with insurance and reimbursement requirements for XELSOURCE.Patient Access Coordinator (PAC)
When prescribed patients choose to opt in for Patient Access Coordinator support, they can rely on a knowledgeable and dedicated Pfizer professional who collaborates with XELSOURCE and can help them understand how their insurance works for their prescribed medication.For those patients who need help with their medication cost-sharing requirements, XELSOURCE can refer patients who appear to be eligible for Medicare Extra Help.
For those patients who need financial assistance, XELSOURCE can refer your patient to Medicaid if your patient appears to be eligible. If turned down, XELSOURCE can evaluate your patient for the Pfizer Patient Assistance Program.
Pfizer Patient Assistance Program—Eligible patients may receive XELJANZ at no charge. See Terms & Conditions.
For those patients who need help with their medication cost-sharing requirements, XELSOURCE can refer patients who appear to be eligible for Medicare Extra Help.
For those patients who
need financial assistance, XELSOURCE can refer your patient to Medicaid if your patient appears to be eligible. If turned down, XELSOURCE can evaluate your patient for the Pfizer Patient Assistance Program.
Pfizer Patient Assistance Program—Eligible patients may receive XELJANZ at no charge. See Terms & Conditions.
If your patients have questions or are in need of additional support, call 1-844-935-5269 or visit www.XELJANZ.com.
INTERIM CARE Rx PROGRAM TERMS & CONDITIONS
PFIZER PATIENT ASSISTANCE PROGRAM ELIGIBILITY CRITERIA
VOUCHER TERMS AND CONDITIONS
By redeeming this voucher, you acknowledge that you currently meet the eligibility criteria and will comply with the terms & conditions described below:
*MA residents may select their pharmacy. Otherwise, this free trial will be supplied through XELSOURCE.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
PP-XEL-USA-9497
SERIOUS INFECTIONS
Patients treated with XELJANZ* are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.
If a serious infection develops, interrupt XELJANZ until the infection is controlled.
Reported infections include:
The most common serious infections reported with XELJANZ included pneumonia, cellulitis, herpes zoster, urinary tract infection, diverticulitis, and appendicitis. Avoid use of XELJANZ in patients with an active, serious infection, including localized infections.
In the UC population, XELJANZ 10 mg twice daily was associated with greater risk of serious infections compared to 5 mg twice daily. Opportunistic herpes zoster infections (including meningoencephalitis, ophthalmologic, and disseminated cutaneous) were seen in patients who were treated with XELJANZ 10 mg twice daily.
The risks and benefits of treatment with XELJANZ should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection, or those who have lived or traveled in areas of endemic TB or mycoses. Viral reactivation including herpes virus and hepatitis B reactivation have been reported. Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with XELJANZ, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.
Caution is also recommended in patients with a history of chronic lung disease, or in those who develop interstitial lung disease, as they may be more prone to infection.
MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)
RA patients 50 years of age and older with at least one CV risk factor, treated with XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily, had a higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke), compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue XELJANZ in patients that have experienced a myocardial infarction or stroke.
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with XELJANZ, particularly in patients who are current or past smokers and patients with other CV risk factors. Inform patients about the symptoms of serious CV events. A XELJANZ 10 mg twice a day (or a XELJANZ XR 22 mg once daily) dosage is not recommended for the treatment of RA or PsA.
THROMBOSIS
Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis, have occurred in patients treated with XELJANZ and other Janus kinase inhibitors used to treat inflammatory conditions. Many of these events were serious and some resulted in death. RA patients 50 years of age and older with at least one CV risk factor treated with XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily compared to TNF blockers had an observed increase in incidence of these events. Avoid XELJANZ in patients at risk. Discontinue XELJANZ and promptly evaluate patients with symptoms of thrombosis.
A XELJANZ 10 mg twice daily (or XELJANZ XR 22 mg once daily) dosage is not recommended for the treatment of RA or PsA. In a long-term extension study in UC, five cases of pulmonary embolism were reported in patients taking XELJANZ 10 mg twice daily, including one death in a patient with advanced cancer. For UC, use XELJANZ at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.
GASTROINTESTINAL PERFORATIONS
Gastrointestinal perforations have been reported in XELJANZ clinical trials, although the role of JAK inhibition is not known. In these studies, many patients with rheumatoid arthritis were receiving background therapy with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). There was no discernible difference in frequency of gastrointestinal perforation between the placebo and the XELJANZ arms in clinical trials of patients with UC, and many of them were receiving background corticosteroids. XELJANZ should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs).
HYPERSENSITIVITY
Angioedema and urticaria that may reflect drug hypersensitivity have been observed in patients receiving XELJANZ and some events were serious. If a serious hypersensitivity reaction occurs, promptly discontinue tofacitinib while evaluating the potential cause or causes of the reaction.
ADVERSE REACTIONS
The most common serious adverse reactions were serious infections. The most commonly reported adverse reactions during the first 3 months in controlled clinical trials in patients with RA with XELJANZ 5 mg twice daily and placebo, respectively, (occurring in greater than or equal to 2% of patients treated with XELJANZ with or without DMARDs) were upper respiratory tract infection, nasopharyngitis, diarrhea, headache, and hypertension. The safety profile observed in patients with active PsA treated with XELJANZ was consistent with the safety profile observed in RA patients.
Adverse reactions reported in ≥5% of patients treated with either 5 mg or 10 mg twice daily of XELJANZ and ≥1% greater than reported in patients receiving placebo in either the induction or maintenance clinical trials for UC were: nasopharyngitis, elevated cholesterol levels, headache, upper respiratory tract infection, increased blood creatine phosphokinase, rash, diarrhea, and herpes zoster.
USE IN PREGNANCY
Available data with XELJANZ use in pregnant women are insufficient to establish a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and the fetus associated with rheumatoid arthritis and UC in pregnancy. In animal studies, tofacitinib at 6.3 times the maximum recommended dose of 10 mg twice daily demonstrated adverse embryo-fetal findings. The relevance of these findings to women of childbearing potential is uncertain. Consider pregnancy planning and prevention for females of reproductive potential.
*Unless otherwise stated, “XELJANZ” in the Important Safety Information refers to XELJANZ, XELJANZ XR, and XELJANZ Oral Solution.
Please see full Prescribing Information, including BOXED WARNING and Medication Guide.